{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:25:24Z","timestamp":1761823524841},"reference-count":102,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Homeopathy"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>\n          \n            Background:\n           Homeopathy is based on treatment by similitude (\u2018like cures like\u2019) administering to sick individuals substances that cause similar symptoms in healthy individuals, employing the secondary and paradoxical action of the organism as therapeutic response. This vital or homeostatic reaction of the organism can be scientifically explained by the rebound effect of drugs, resulting in worsening of symptoms after suspension of treatment. Bisphosphonates (BPs) reduce \u2018typical\u2019 fractures in patients with osteoporosis, but recent studies report \u2018atypical\u2019 fractures of the femur after stopping the BPs, a rebound effect may be the causal mechanism.<\/jats:p><jats:p>\n          \n            Method:\n           Review of the literature concerning the relationship between atypical femoral fractures and antiresorptive drugs (bisphosphonates), identifying the pathogenesis of this adverse event.<\/jats:p><jats:p>\n          \n            Results:\n           Several studies have described multiple cases of \u2018atypical\u2019 low-impact subtrochanteric stress fractures or complete fractures of the femur. These fractures are often bilateral, preceded by pain in the affected thigh, may have a typical X-ray appearance, and may delayed healing. Rebound of osteoclastic activity after suspension of antiresorptive drugs is a plausible mechanism to explain this phenomenon.<\/jats:p><jats:p>\n          \n            Conclusion:\n           As for other classes of drugs, the rebound effect of antiresorptive drugs supports Hahnemann's similitude principle (primary action of the drugs followed by secondary and opposite action of the organism), and clarifies this \u2018unresolved\u2019 issue. Unfortunately, the rebound effect is little discussed among health professionals, depriving them of important knowledge ensure safe management of drugs.<\/jats:p>","DOI":"10.1016\/j.homp.2012.07.001","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T06:32:08Z","timestamp":1350973928000},"page":"231-242","source":"Crossref","is-referenced-by-count":15,"title":["Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude"],"prefix":"10.1055","volume":"101","author":[{"given":"Marcus Zulian","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.homp.2011.01.002","article-title":"New homeopathic medicines: use of modern drugs according to the principle of similitude","volume":"100","author":"M.Z Teixeira","year":"2011","journal-title":"Homeopathy"},{"key":"ref2","volume-title":"Organon of medicine. (Translated by William Boericke)","author":"S Hahnemann","year":"1991","edition":"6th edn"},{"key":"ref3","volume-title":"Semelhante cura semelhante: o princ\u00edpio de cura homeop\u00e1tico fundamentado pela racionalidade m\u00e9dica e cient\u00edfica","author":"M.Z Teixeira","year":"1998"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1054\/homp.1999.0301","article-title":"Similitude in modern pharmacology","volume":"88","author":"M.Z Teixeira","year":"1999","journal-title":"Homeopathy"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.homp.2006.06.004","article-title":"Evidence of the principle of similitude in modern fatal iatrogenic events","volume":"95","author":"M.Z Teixeira","year":"2006","journal-title":"Homeopathy"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.homp.2006.11.009","article-title":"NSAIDs, myocardial infarction, rebound effect and similitude","volume":"96","author":"M.Z Teixeira","year":"2007","journal-title":"Homeopathy"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.homp.2007.02.001","article-title":"Bronchodilators, fatal asthma, rebound effect and similitude","volume":"96","author":"M.Z Teixeira","year":"2007","journal-title":"Homeopathy"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.homp.2009.02.004","article-title":"Antidepressants, suicidality and rebound effect: evidence of similitude?","volume":"98","author":"M.Z Teixeira","year":"2009","journal-title":"Homeopathy"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.homp.2010.01.001","article-title":"Statins withdrawal, vascular complications, rebound effect and similitude","volume":"99","author":"M.Z Teixeira","year":"2010","journal-title":"Homeopathy"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.homp.2011.05.003","article-title":"Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude","volume":"100","author":"M.Z Teixeira","year":"2011","journal-title":"Homeopathy"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1503\/cmaj.081720","article-title":"Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study","volume":"181","author":"G. Ioannidis","year":"2009","journal-title":"CMAJ"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00198-008-0743-7","article-title":"The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study","volume":"20","author":"A. Papaioannou","year":"2009","journal-title":"Osteoporos Int"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","article-title":"Meta-analysis: excess mortality after hip fracture among older women and men","volume":"152","author":"P. Haentjens","year":"2010","journal-title":"Ann Intern Med"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.injury.2008.03.022","article-title":"Mortality following hip fracture: trends and geographical variations over the last 40 years","volume":"39","author":"S. Haleem","year":"2008","journal-title":"Injury"},{"issue":"09","key":"ref15","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"M.T. Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4158\/EP08306.ORR1","article-title":"Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates","volume":"15","author":"F Cosman","year":"2009","journal-title":"Endocr Pract"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"R.G.G. Russell","year":"2008","journal-title":"Osteoporos Int"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"S.C. Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"24","key":"ref22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Long-term Extension (FLEX): a randomized trial","volume":"296","author":"D.M. Black","year":"2006","journal-title":"JAMA"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"N.B. Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.rdc.2011.08.001","article-title":"Long-term safety concerns of antiresorptive therapy","volume":"37","author":"J. Zhang","year":"2011","journal-title":"Rheum Dis Clin North Am"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"A.S. Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"E. Shane","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00005373-199707000-00027","article-title":"Specific features associated with femoral shaft fractures caused by low-energy trauma","volume":"43","author":"S. Salminen","year":"1997","journal-title":"J Trauma"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-009-0962-6","article-title":"Fragility fractures of the hip and femur: incidence and patient characteristics","volume":"21","author":"J.W. Nieves","year":"2010","journal-title":"Osteoporos Int"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996\u20132007","volume":"26","author":"Z. Wang","year":"2011","journal-title":"J Bone Miner Res"},{"key":"ref30","volume-title":"Incidence of subtrochanteric and diaphyseal fractures in older white women: data from the study of osteoporotic fractures","author":"M.P. Kelly","year":"2010"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.injury.2008.09.010","article-title":"Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients","volume":"40","author":"W. Ekstrom","year":"2009","journal-title":"Injury"},{"key":"ref32","volume-title":"US Food and Drug Administration ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures","year":"2010"},{"issue":"01","key":"ref33","first-page":"18","article-title":"Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk","volume":"64","author":"J.P Schneider","year":"2009","journal-title":"Geriatrics"},{"issue":"05","key":"ref34","first-page":"567","article-title":"Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates): a systemic review of literature","volume":"76","author":"S. Agarwal","year":"2010","journal-title":"Acta Orthop Belg"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11914-010-0007-2","article-title":"Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates","volume":"8","author":"J.W. Nieves","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"A. Giusti","year":"2010","journal-title":"Bone"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective","volume":"27","author":"S. Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"01","key":"ref38","first-page":"31","article-title":"Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate","volume":"61","author":"J.P Schneider","year":"2006","journal-title":"Geriatrics"},{"issue":"06","key":"ref39","first-page":"485","article-title":"Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate","volume":"13","author":"R.K. Cheung","year":"2007","journal-title":"Hong Kong Med J"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0883-5403(97)90184-4","article-title":"Subtrochanteric stress fracture of the femur following total knee arthroplasty","volume":"12","author":"D.A. Kumm","year":"1997","journal-title":"J Arthroplasty"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00402-007-0373-0","article-title":"Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report","volume":"127","author":"B. Demiralp","year":"2007","journal-title":"Arch Orthop Trauma Surg"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1359\/jbmr.090408","article-title":"Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility","volume":"24","author":"M.P. Somford","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00068-005-1421-5","article-title":"Bilateral mid-diaphyseal femoral stress fractures in the elderly","volume":"31","author":"G. Husada","year":"2005","journal-title":"Eur J Trauma"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11999-009-0725-x","article-title":"Case reports: two femoral insufficiency fractures after long-term alendronate therapy","volume":"467","author":"A.S. Sayed-Noor","year":"2009","journal-title":"Clin Orthop Relat Res"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"C.V. Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"08","key":"ref46","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"M. Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"ref47","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMc0910389","article-title":"Atypical femoral fractures and bisphosphonate use","volume":"362","author":"C.M. Girgis","year":"2010","journal-title":"N Engl J Med"},{"key":"ref48","volume-title":"Bisphosphonates for postmenopausal osteoporosis","author":"S.E Papapoulos","year":"2008","edition":"7th edn"},{"issue":"05","key":"ref49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how do they work?","volume":"22","author":"S.E Papapoulos","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"B.A. Lenart","year":"2009","journal-title":"Osteoporos Int"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","article-title":"Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register based national cohort study","volume":"24","author":"B. Abrahamsen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"ref52","volume-title":"Subtrochanteric and diaphyseal femur fractures in patients during long-term alendronate therapy: expanded and extended national register-based cohort study 37th European Symposium on Calcified Tissues (ECTS 2010)","author":"B. Abrahamsen","year":"2010"},{"key":"ref53","volume-title":"Risk of femoral shaft and subtrochanteric fractures in users of bisphophonates, raloxifene and strontium ranelate","author":"P. Vestergaard","year":"2010"},{"issue":"19","key":"ref54","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"D.M. Black","year":"2010","journal-title":"N Engl J Med"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women","volume":"305","author":"L.Y. Park-Wyllie","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1210\/jc.2010-1571","article-title":"Cumulative alendronate dose and the long-term absolute aisk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis","volume":"95","author":"B. Abrahamsen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"ref57","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"J. Schilcher","year":"2011","journal-title":"N Engl J Med"},{"issue":"05","key":"ref58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002230010036","article-title":"Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage","volume":"69","author":"J. Li","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib","volume":"15","author":"T. Mashiba","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"T. Mashiba","year":"2001","journal-title":"Bone"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S8756-3282(00)00284-2","article-title":"Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?","volume":"27","author":"T. Hirano","year":"2000","journal-title":"Bone"},{"issue":"02\/03","key":"ref62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/03008200290000934","article-title":"Changes in bone remodeling rate influence the degree of mineralization of bone","volume":"43","author":"G. Boivin","year":"2002","journal-title":"Connect Tissue Res"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1359\/jbmr.2003.18.6.1012","article-title":"Aging and microstructural compartments in human compact bone","volume":"18","author":"O. Akkus","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"03","key":"ref64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(02)00975-4","article-title":"Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females","volume":"32","author":"T.E. Ciarella","year":"2003","journal-title":"Bone"},{"issue":"01","key":"ref65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00774-004-0540-0","article-title":"Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease","volume":"23","author":"M. Kitano","year":"2005","journal-title":"J Bone Miner Metab"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"H.N. Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"issue":"09","key":"ref67","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1210\/endo.137.9.8756585","article-title":"The human osteoclast precursor circulates in the monocyte fraction","volume":"137","author":"Y. Fujikawa","year":"1996","journal-title":"Endocrinology"},{"issue":"06","key":"ref68","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bone.2008.02.001","article-title":"How can bone turnover modify bone strength independent of bone mass?","volume":"42","author":"C.J Hernandez","year":"2008","journal-title":"Bone"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"J.E. Brown","year":"2005","journal-title":"JNCI"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin","volume":"299","author":"G. Heiss","year":"2008","journal-title":"JAMA"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.AOG.0000114986.14806.37","article-title":"Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment","volume":"103","author":"J. Yates","year":"2004","journal-title":"Obstet Gynecol"},{"issue":"11","key":"ref72","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers","volume":"87","author":"J.C. Gallagher","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(81)91848-1","article-title":"Bone mass in postmenopausal women after withdrawal of oestrogen\/gestagen replacement therapy","volume":"1","author":"C. Christiansen","year":"1981","journal-title":"Lancet"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial","volume":"137","author":"S.L. Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"P.D. Miller","year":"2008","journal-title":"Bone"},{"issue":"08","key":"ref76","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"S.R. Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"S 01","key":"ref77","first-page":"S1","article-title":"Four years of denosumab exposure in women with postmenopausal osteoporosis: results from the first year extension of the FREEDOM trial","volume":"25","author":"S. Papapoulos","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"02","key":"ref78","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"P.D. Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref79","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"H.G. Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"J.A. Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"ref81","volume-title":"The importance of pharmacovigilance","author":"World Health Organization (WHO)","year":"2002"},{"key":"ref82","volume-title":"Webster's new World medical dictionary","year":"2008","edition":"3rd edn"},{"issue":"05","key":"ref83","first-page":"383","article-title":"Drug withdrawal syndromes \u2013 a literature review","volume":"133","author":"G.C. Hodding","year":"1980","journal-title":"West J Med"},{"issue":"02","key":"ref84","first-page":"455","article-title":"Antidepressant withdrawal reactions","volume":"56","author":"R.M Wolfe","year":"1997","journal-title":"Am Fam Physician"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF01185522","article-title":"Influence of some monoamine oxidase inhibitors on the sleep-wakefulness cycle of the cat","volume":"18","author":"T.N. Oniani","year":"1988","journal-title":"Neurosci Behav Physiol"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.111.183285","article-title":"Drug discontinuation effects are part of the pharmacology of a drug","volume":"339","author":"M.M Reidenberg","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"07","key":"ref87","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1359\/jbmr.060401","article-title":"Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women","volume":"21","author":"R. Zoehrer","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"S 01","key":"ref88","first-page":"S10.","article-title":"Long-term treatment with oral bisphosphonates in postmenopausal women: effects on the degree of mineralization and microhardness of bone","volume":"23","author":"G. Boivin","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1359\/jbmr.090702","article-title":"Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the Fracture Intervention Trial Long-term Extension (FLEX)","volume":"25","author":"P. Roschger","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"04","key":"ref90","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1359\/jbmr.2000.15.4.754","article-title":"Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies","volume":"15","author":"P.M. Chavassieux","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"06","key":"ref91","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"P.M. Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"issue":"05","key":"ref92","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"E.F. Eriksen","year":"2002","journal-title":"Bone"},{"issue":"S 05","key":"ref93","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"M.R. Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"issue":"02","key":"ref94","first-page":"265","article-title":"Bisphosphonate-related osteonecrosis of the jaw","volume":"52","author":"M.A. Brozoski","year":"2012","journal-title":"Rev Bras Reumatol"},{"issue":"22","key":"ref95","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis \u2013 where do we go from here?","volume":"366","author":"M. Whitaker","year":"2012","journal-title":"N Engl J Med"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1542-2011.2011.00135.x","article-title":"Osteoporosis update","volume":"56","author":"K.D. Schuiling","year":"2011","journal-title":"J Midwifery Womens Health"},{"issue":"07","key":"ref97","first-page":"21","article-title":"Evaluation and treatment of bone disease after fragility fracture","volume":"63","author":"M.V Gibson","year":"2008","journal-title":"Geriatrics"},{"issue":"03","key":"ref98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"S.K. Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report","volume":"22","author":"R. Rizzoli","year":"2011","journal-title":"Osteoporos Int"},{"key":"ref100","volume-title":"Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)","author":"National Institute for Health and Clinical Excellence","year":"2010"},{"issue":"12","key":"ref101","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"O. Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"d4094.","DOI":"10.1136\/bmj.d4094","article-title":"Discontinuation of low dose aspirin and risk of myocardial infarction: case\u2013control study in UK primary care","volume":"343","author":"L.A. Rodr\u00edguez","year":"2011","journal-title":"BMJ"},{"issue":"08","key":"ref103","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1212\/WNL.0b013e31820d62b5","article-title":"Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study","volume":"76","author":"L.A. Garc\u00eda Rodr\u00edguez","year":"2011","journal-title":"Neurology"},{"issue":"39","key":"ref104","first-page":"69","article-title":"Rebound effect of drugs: fatal risk of conventional treatment and pharmacological basis of homeopathic treatment","volume":"11","author":"M.Z Teixeira","year":"2012","journal-title":"Int J High Dilution Res"},{"key":"ref105","volume-title":"New homeopathic medicines: use of modern drugs according to the principle of similitude","author":"M.Z Teixeira","year":"2010"}],"container-title":["Homeopathy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1475491612000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1475491612000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1016\/j.homp.2012.07.001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T13:15:29Z","timestamp":1637846129000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1016\/j.homp.2012.07.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":102,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2017,12,29]]},"published-print":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1016\/j.homp.2012.07.001","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1475-4916","1476-4245"],"issn-type":[{"value":"1475-4916","type":"print"},{"value":"1476-4245","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}